AACHEN, Germany & CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8, London AIM: PAI) today announces positive results from a meta-analysis of Phase II and Phase III data generated with morphine-6-glucuronide (M6G). According to PAION, applying the findings should improve the probability of success for the development program and will facilitate the planning of future studies. Accordingly, PAION is now re-launching the partnering process for M6G.
